[Change in intraperitoneal shunt after DAA treatment for hepatitis C].

Michio Kubota, Yasuharu Kikuchi, Shintaro Kamimukai, Nobuhiro Yamada, Yusuke Masuda, Kaori Kinjo, Naoto Fujita, Akihiko Nakagawa, Masami Shinozaki
{"title":"[Change in intraperitoneal shunt after DAA treatment for hepatitis C].","authors":"Michio Kubota, Yasuharu Kikuchi, Shintaro Kamimukai, Nobuhiro Yamada, Yusuke Masuda, Kaori Kinjo, Naoto Fujita, Akihiko Nakagawa, Masami Shinozaki","doi":"10.11405/nisshoshi.121.580","DOIUrl":null,"url":null,"abstract":"<p><p>Improvement and worsening of portal hypertension after direct acting antiviral agent (DAA) treatment for hepatitis C virus-related cirrhosis have been reported, and a consensus remains elusive. In this study, we underscored on the intraperitoneal shunt formed via portal hypertension and examined how the shunt system confirmed by computed tomography (CT) changes before and after treatment in cases in which sustained virological response (SVR) was attained with DAAs. Of the cases in which we achieved an SVR of 24 with DAA treatment for hepatitis C virus-related cirrhosis at our hospital, 83 cases in which CT images were taken before and after treatment were investigated. If the intraperitoneal shunt diameter changed by 20% or more, it was analyzed as an increase or decrease. In 29 patients, intraperitoneal shunt enlargement was noted. When examining factors related to the increase, multivariate analysis detected the FIB4 index at the end of the DAA treatment. Conversely, only four cases were observed in which the size decreased. At the end of treatment, the FIB4 index was the most important factor in increasing the intraperitoneal shunt after DAA treatment for hepatitis C virus-related cirrhosis, and fibrosis was believed to be an influencing factor.</p>","PeriodicalId":35808,"journal":{"name":"Japanese Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11405/nisshoshi.121.580","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Improvement and worsening of portal hypertension after direct acting antiviral agent (DAA) treatment for hepatitis C virus-related cirrhosis have been reported, and a consensus remains elusive. In this study, we underscored on the intraperitoneal shunt formed via portal hypertension and examined how the shunt system confirmed by computed tomography (CT) changes before and after treatment in cases in which sustained virological response (SVR) was attained with DAAs. Of the cases in which we achieved an SVR of 24 with DAA treatment for hepatitis C virus-related cirrhosis at our hospital, 83 cases in which CT images were taken before and after treatment were investigated. If the intraperitoneal shunt diameter changed by 20% or more, it was analyzed as an increase or decrease. In 29 patients, intraperitoneal shunt enlargement was noted. When examining factors related to the increase, multivariate analysis detected the FIB4 index at the end of the DAA treatment. Conversely, only four cases were observed in which the size decreased. At the end of treatment, the FIB4 index was the most important factor in increasing the intraperitoneal shunt after DAA treatment for hepatitis C virus-related cirrhosis, and fibrosis was believed to be an influencing factor.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[DAA治疗丙型肝炎后腹腔分流的变化]。
直接作用抗病毒药物(DAA)治疗丙型肝炎病毒相关肝硬化后,门静脉高压改善或恶化的情况时有报道,但至今仍未达成共识。在本研究中,我们强调了通过门脉高压形成的腹腔内分流,并研究了在使用 DAAs 获得持续病毒学应答(SVR)的病例中,通过计算机断层扫描(CT)确认的分流系统在治疗前后的变化情况。在我院使用 DAA 治疗丙型肝炎病毒相关性肝硬化并获得 24 例 SVR 的病例中,有 83 例在治疗前后拍摄了 CT 图像,我们对这些病例进行了调查。如果腹腔内分流管直径的变化达到或超过 20%,则分析为增加或减少。29例患者的腹腔内分流管扩大。在研究与增大相关的因素时,多变量分析检测到了 DAA 治疗结束时的 FIB4 指数。相反,仅有四例患者的分流大小有所减小。在治疗结束时,FIB4指数是丙型肝炎病毒相关肝硬化患者接受DAA治疗后腹腔分流增大的最重要因素,而纤维化被认为是一个影响因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Japanese Journal of Gastroenterology
Japanese Journal of Gastroenterology Medicine-Gastroenterology
CiteScore
0.20
自引率
0.00%
发文量
0
期刊介绍: The Journal of Gastroenterology, which is the official publication of the Japanese Society of Gastroenterology, publishes Original Articles (Alimentary Tract/Liver, Pancreas, and Biliary Tract), Review Articles, Letters to the Editors and other articles on all aspects of the field of gastroenterology. Significant contributions relating to basic research, theory, and practice are welcomed. These publications are designed to disseminate knowledge in this field to a worldwide audience, and accordingly, its editorial board has an international membership.
期刊最新文献
[A case of inflammatory myofibroblastic tumor with rapidly progressive growth arising from the retroperitoneum]. [Autoimmune hepatitis:an up-to-date review]. [A case of mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) diagnosed by re-biopsy of the enlarged primary tumor during chemotherapy for gastric adenocarcinoma]. [A case of pulmonary tuberculosis developed during chemotherapy for local advanced colon cancer]. [Autoimmune hepatobiliary disease -up to date].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1